Amendments to the Claims

Please amend the claims as indicated below:

- 1-10 (Canceled).
- 11. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound is CNI-1493.
 - 12. (Canceled).
- 13. (Previously Presented) The method according to Claim 11, wherein the disease or disorder is modulated by inhibiting signaling along a pathway within the cascade.
- 14. (Previously Presented) The method according to Claim 11, further comprising administering an additional therapeutic agent.
- 15. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an anti-viral agent.
- 16. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.
- 17. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an HIV protease inhibitor.
- 18. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a preintegration complex inhibitor.

19-20 (Canceled).

21. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound has the formula:

wherein X_2 = GhyCH-, GhyCCH₃- or H-; X_1 , X'_1 and X'_2 independently = GhyCH- or GhyCCH₃-; Z= -NH(CO)NH-, -(C₆H₄)-, -(C₅NH₃)- or -A-(CH₂)_n-A-, n=2-10, which is unsubstituted, mono- or di-C-methyl substituted, or a mono or di-unsaturated derivative thereof; and A independently = -NH(CO)-, -(CO)NH-, -NH(CO)NH-, -NH- or -O-; and salts thereof.

22. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound has the formula:

wherein X_1 and $X_2 = H$; X'_1 and X'_2 independently = GhyCH- or GhyCCH₃-; Z = -A(CH₂)_n-A-, n = 3-8; and A = -NH(CO)-, -(CO)NH- or -NH(CO)NH-; and salts thereof.

23. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound has the formula:

$$z$$
 z
 z

wherein X_1 , and $X_2 = H$; X'_1 and X'_2 independently = GhyCH- or GhyCCH₃-, and $Z = -O-(CH_2)_2-O-$.

24. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound has the formula:

wherein X_2 = GhyCH-, GhyCCH₃- or H-; X_1 , X'_1 and X'_2 = GhyCH- or GhyCCH₃-; and Z = -O-(CH₂)_n-O-, n = 2-10, and salts thereof.

25. (Currently Amended) The method according to Claim 20, A method for treating HIV, comprising administering an effective HIV-treating amount of a guanylhydrazone-substituted compound to a subject known to have HIV, wherein the guanylhydrazone-substituted compound has the formula:

$$\begin{array}{c|c} X_1 & & & \\ \hline & & \\ X_2 & & \\ \hline \end{array}$$

wherein n=3-8; X_2 and X'_2 = GhyCH-, GhyCCH₃- or H-; X_1 and X'_1 = GhyCH- or GhyCCH₃-; and salts thereof.

- 26. (New) The method of claim 21, further comprising administering one or more retrovirus inhibitor selected from the group consisting of reverse transcriptase inhibitor, HIV protease inhibitor, and preintegration complex inhibitor.
- 27. (New) The method of claim 26, wherein the retrovirus inhibitor is one or more reverse transcriptase inhibitor selected from the group consisting of 3'azido-3'-thymidine (AZT); dideoxyinosine (ddl); 2',3'-dideoxyadenosine (ddA); 2',3'-dideoxyguanosine (ddG); 2',3'-dideoxyinosine (ddI); 2',3'-dideoxycytidine (ddC); 2',3'-dideoxythymidine (ddT); 2',3'-dideoxy-dideoxythymidine (d4T); 3TC; 2',3'-dideoxy-2'-fluoronucleosides; 2',3'-dideoxy-2'-fluoroadenosine; 2',3'-dideoxy-2'-fluorothymidine; 2',3'-dideoxy-2'-fluorocytosine; 2',3'-dideoxy-2'-fluoronucleoside; 2',3'-dideoxy-2'-fluorothymidine (F-ddA); 2',3'-dideoxy-2'-beta-fluoroadenosine (F-ddA); 2',3'-dideoxy-2'-beta-fluorocytosine (F-ddC).
- 28. (New) The method of claim 21, wherein the guanylhydrazone-substituted compound is a salt.
- 29. (New) The method of claim 28, wherein the salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, acetate, citrate, tartrate, lactate, and malate salt.

- 30. (New) The method of claim 25, further comprising administering one or more retrovirus inhibitor selected from the group consisting of reverse transcriptase inhibitor, HIV protease inhibitor, and preintegration complex inhibitor.
- 31. (New) The method of claim 30, wherein the retrovirus inhibitor is one or more reverse transcriptase inhibitor selected from the group consisting of 3'azido-3'-thymidine (AZT); dideoxyinosine (ddl); 2',3'-dideoxyadenosine (ddA); 2',3'-dideoxyguanosine (ddG); 2',3'-dideoxyinosine (ddI); 2',3'-dideoxycytidine (ddC); 2',3'-dideoxythymidine (ddT); 2',3'-dideoxy-dideoxythymidine (d4T); 3TC; 2',3'-dideoxy-2'-fluoronucleosides; 2',3'-dideoxy-2'-fluoroadenosine; 2',3'-dideoxy-2'-fluoroinosine; 2',3'-dideoxy-2'-fluorothymidine; 2',3'-dideoxy-2'-fluorocytosine; 2',3'-dideoxy-2'-fluoronucleoside; 2',3'-dideoxy-2'-dideoxy-2'-beta-fluoroadenosine (F-ddA); 2',3'-dideoxy-2'-beta-fluorosine (F-ddC).
- 32. (New) The method of claim 25, wherein the guanylhydrazone-substituted compound is a salt.
- 33. (New) The method of claim 32, wherein the salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, acetate, citrate, tartrate, lactate, and malate salt.